Optimizing steroid treatment for UC patients with CMV colitis: a multicenter real-world study

Area of Science:

• Gastroenterology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Ulcerative colitis (UC) patients with concurrent cytomegalovirus (CMV) colitis experience increased disease severity and worse prognosis.
• Antiviral therapy is beneficial, but optimal immunosuppressive management, especially steroid use, remains debated.

Purpose of the Study:

• To evaluate the impact of different steroid strategies on outcomes in hospitalized UC patients with concomitant CMV colitis.
• To compare colectomy rates and clinical response/remission based on steroid management post-CMV diagnosis.

Main Methods:

• A retrospective two-center study included hospitalized patients with moderate-to-severe UC and CMV colitis.
• Patients were stratified into three groups: intensified steroid treatment, steroid tapering, or steroid non-initiation post-CMV diagnosis.
• Multivariate logistic regression analyzed colectomy risk at Weeks 26 and 52, and clinical response/remission at Days 7 and 14, adjusting for confounders.

Main Results:

• The intensified steroid group showed significantly lower colectomy risk at Week 26 (adjusted OR=0.1) and Week 52 (adjusted OR=0.1) compared to the non-initiation group.
• Higher Day 7 clinical response rates were observed in the intensified group (adjusted OR=4.5) versus non-initiation.
• No significant differences in short- or long-term outcomes were found between the intensified and tapering steroid groups.

Conclusions:

• Steroid strategies for UC with CMV colitis necessitate individualized adjustments based on prior steroid exposure.
• Intensified steroid treatment is superior to steroid non-initiation for improving short-term response and reducing long-term colectomy risk.
• Individualized therapy is crucial for balancing immediate and long-term outcomes in these complex cases.